TRIO-US is a Site Management Organization (SMO) made up of a committed group of more than 10 community oncologists across the United States interested in participating in translational research studies. TRIO-US network sites are responsible for executing on clinical trials brought to them by the UCLA Jonsson Comprehensive Cancer Center (JCCC) Clinical Research Unit (CRU). Many of the TRIO-US Network sites have participated in clinical trials since the inception of the network over 20 years ago.
History of TRIO-US and our affiliates:
Historically, the UCLA Jonsson Comprehensive Cancer Center (JCCC) partnered with large private practices to offer oncology patients earlier access to leading-edge therapeutic trials. This organization consisted of sites affiliated under the JCCC. The name of this union of community practice was the Community Oncology Research Network (CORN). In 1995, the organization formally the name to Translational Oncology Research International (TORI), established itself as a non-profit, 501c(3), and a site management organization (SMO). Subsequently, the name was changed in 2011 to Translational Research in Oncology-US Network (TRIO-US) in alliance with international affiliate in TRIO. The Network operates under a Memorandum of Understanding (MOU) between the UCLA Chancellor’s Office and the JCCC stipulating the primary purpose of TRIO-US is to offer important and select cutting-edge therapeutic trials to participants outside the immediate catchment area and nationwide, which supports greater accrual to JCCC clinical trials. This arrangement has been particularly effective at giving JCCC investigators access to the wider potential patient pool needed to conduct proof-of-concept and early phase clinical trials.
TRIO – International Affiliate
TRIO, formerly Breast Cancer International Research Group (BCIRG) is a full service Academic Research Organization (ARO) with offices in Edmonton, Paris and Montevideo. TRIO-Global was first established in 1997 as BCIRG and as part of the Alberta Cancer Board. The first trial conducted by BCIRG was a pivotal breast cancer study which led to the registration of docetaxel in the adjuvant treatment of breast cancer. BCIRG was incorporated as CIRG in 1999, an operational structure which adhered to comprehensive pharmaceutical industry standards. CIRG, UCLA-TORL, and TORI merged in 2005 to become TRIO. In 2011, CIRG, in conjunction with TORI, officially changed their name to TRIO-Global. Since the inception of TRIO, it has established a reputation as a leader in the clinical oncology research community. TRIO has built a network of more than 300 research sites, with over 500 investigators, to successfully run international trials. Like TRIO-US, TRIO benefits from the expertise at UCLA-TORL and its findings which form the basis of its study designs and strategy.
TRIO, a not-for-profit organization, is a global leader in translational oncology research through scientific innovation, excellence in trial development and execution, and collaboration with investigators and industry. TRIO has three values which the organization follows: integrity, teamwork and passion. The ultimate goal is to improve the survival and quality of life of patients with cancer.
UCLA-TORL – Laboratory/Science Affiliate
UCLA-TORL is the basic science laboratory where pre-clinical data is generated for translation into humans. The pre-clinical data from UCLA-TORL are developed into early phase proof of concept clinical trials – possibly expanding to phase II and III trials - for execution locally at UCLA, in addition to the TRIO-US Network nationally, or with TRIO internationally.